Form 4: Alkermes Director Christopher Wright Equity Update

Director Christopher I. Wright exercised stock options and received new equity grants in Alkermes plc.

Summary

• Director Christopher I. Wright acquired 6,142 ordinary shares through the exercise of restricted stock units.
• 1,475 shares were withheld by the company at a price of $36.95 to cover tax obligations.
• The director received a new grant of 11,538 non-qualified stock options with an exercise price of $36.98.
• The director received a new grant of 5,409 restricted stock units.
• Following these transactions, the director holds 27,680 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a significant equity stake of 27,680 shares, aligning interests with shareholders.
• New equity grants demonstrate continued commitment and retention of key leadership.

Negatives

• The transaction involved the withholding of shares for tax purposes, which is a standard but routine reduction in total holdings.

Risks

• Future value of equity grants is dependent on the company's share price performance over the vesting period.

Future Outlook

The new equity awards vest in full on the earlier of the one-year anniversary of the grant or the date of the next annual general meeting occurring at least 50 weeks after the grant.

Management Comments

• Each restricted stock unit represents a contingent right to receive one ordinary share.

Industry Context

StockSavvy.ai notes that routine equity grants and exercises by directors are standard corporate governance practices in the biopharmaceutical sector, reflecting typical compensation structures rather than signaling shifts in company strategy.

Comparison to Industry Standards

• The use of restricted stock units and stock options as director compensation is consistent with standard practices for mid-cap pharmaceutical companies.
• Tax withholding at the time of vesting is a standard administrative procedure for equity-based compensation.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensation-related transactions.

Next Steps

• Vesting of the newly granted stock options and restricted stock units on or before May 20, 2027.

Key Dates

Keywords

Alkermes, ALKS, Director, Insider Trading, Equity Compensation, Form 4